An inducible knockout mouse to model the cellautonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias by Mirantes Barbeito, Cristina et al.
dmm.biologists.org710
INTRODUCTION
PTEN (phosphatase and tensin homolog deleted on chromosome
10) encodes a dual lipid and protein phosphatase that plays a crucial
role in the phosphatidylinositol-3-kinase–Akt–mammalian-target-
of-rapamycin (PI3K-AKT-mTOR) signaling pathway. PTEN
function antagonizes PI3K by catalyzing the dephosphorylation of
phosphatidylinositol (3,4,5)-trisphosphate [PIP3; also known as
PtdIns(3,4,5)P3] to phosphatidylinositol (4,5)-bisphosphate [PIP2;
also known as PtdIns(4,5)P2] (Maehama and Dixon, 1998; Myers
et al., 1997). Loss of PTEN function leads to increased levels of
PIP3 and a potent activation of 3-phosphoinositide-dependent
kinase (PDK) and Akt that stimulates cell growth and survival (Song
et al., 2012; Stambolic et al., 1998; Sun et al., 1999).
PTEN is one of the most frequently mutated tumor suppressor
genes in human cancers. The tumor suppressive function of PTEN
is attributed to chromosome region 10q23, which is partially or
completely deleted in multiple neoplasias (Li et al., 1997; Steck et
al., 1997). Soon after, germline mutations of the PTEN gene were
identified in patients with Cowden disease (Liaw et al., 1997). Since
then, loss-of-function mutations of PTEN have been reported in
many human sporadic cancers, including glioblastoma and thyroid,
breast, colon, prostate or endometrial carcinomas, as well as in
familiar cancer predisposition syndromes known as PTEN tumor
hamartoma syndromes (PTHS) (Hollander et al., 2011).
PTEN-knockout (KO) mouse models have provided evidence for
the role of PTEN in carcinogenesis. Mice with monoallelic deletion
of PTEN (PTEN+/−) develop neoplasms in multiple organs,
including the endometrium, breast, prostate, gastrointestinal tract,
thyroid and lymphoid tissues (Di Cristofano et al., 1998;
Podsypanina et al., 1999; Suzuki et al., 1998). PTEN+/− provides a
good tool to model the neoplastic phenotype observed in
individuals with PTHS (Stambolic et al., 2000). Unfortunately, the
embryonic lethality of mice with biallelic excision of PTEN has
limited the study of complete PTEN ablation in the development
of cancer. Such limitation has been solved by the generation of
PTEN conditional-KO mice, which carry both PTEN alleles flanked
by loxP sites (Lesche et al., 2002). To generate spatial and temporal
control of PTEN deletion, conditional-KO mice have been bred
with mouse strains expressing Cre recombinase under tissue-
specific or inducible promoters. Such a strategy allowed biallelic
ablation of PTEN in different cell types or organs (Knobbe et al.,
2008; Suzuki et al., 2008), such as the adrenal gland (Korpershoek
et al., 2009), breast (Li et al., 2002), thyroid (Yeager et al., 2007),
prostate (Ma et al., 2005; Wang et al., 2003), astrocytes (Fraser et
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SUMMARY
PTEN is one of the most frequently mutated tumor suppressor genes in human cancers. The role of PTEN in carcinogenesis has been validated by
knockout mouse models. PTEN heterozygous mice develop neoplasms in multiple organs. Unfortunately, the embryonic lethality of biallelic excision
of PTEN has inhibited the study of complete PTEN deletion in the development and progression of cancer. By crossing PTEN conditional knockout
mice with transgenic mice expressing a tamoxifen-inducible Cre-ERT under the control of a chicken actin promoter, we have generated a tamoxifen-
inducible mouse model that allows temporal control of PTEN deletion. Interestingly, administration of a single dose of tamoxifen resulted in PTEN
deletion mainly in epithelial cells, but not in stromal, mesenchymal or hematopoietic cells. Using the mT/mG double-fluorescent Cre reporter mice,
we demonstrate that epithelial-specific PTEN excision was caused by differential Cre activity among tissues and cells types. Tamoxifen-induced deletion
of PTEN resulted in extremely rapid and consistent formation of endometrial in situ adenocarcinoma, prostate intraepithelial neoplasia and thyroid
hyperplasia. We also analyzed the role of PTEN ablation in other epithelial cells, such as the tubular cells of the kidney, hepatocytes, colonic epithelial
cells or bronchiolar epithelium, but those tissues did not exhibit neoplastic growth. Finally, to validate this model as a tool to assay the efficacy of
anti-tumor drugs in PTEN deficiency, we administered the mTOR inhibitor everolimus to mice with induced PTEN deletion. Everolimus dramatically
reduced the progression of endometrial proliferations and significantly reduced thyroid hyperplasia. This model could be a valuable tool to study
the cell-autonomous mechanisms involved in PTEN-loss-induced carcinogenesis and provides a good platform to study the effect of anti-neoplastic
drugs on PTEN-negative tumors.
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al., 2004) or hepatocytes (Horie et al., 2004). Temporal control of
PTEN deletion has been achieved by breeding PTEN conditional-
KO mice with mice expressing tamoxifen-inducible Cre
recombinase (Cre-ERT) (Feil et al., 1996; Metzger et al., 1995) under
the control of the Rosa26 promoter (R26Cre-ERT) (Lu et al., 2007).
In this mouse model, tamoxifen causes PTEN excision in a broad
spectrum of cells, leading to the development of multiple
malignancies. Despite many mouse models for tissue-specific
deletion of PTEN being available, the number of mouse models for
both inducible and cell-type-specific deletion of PTEN is limited.
So far, tamoxifen-inducible and polyinosine-polycytidine PTEN
deletion has been achieved in adult prostatic epithelium and
hematopoietic stem cells, respectively (Ratnacaram et al., 2008;
Yilmaz et al., 2006). In both models, induction of PTEN
recombination led to the development of prostatic neoplasias and
myeloproliferative disorders, respectively. For other tissues, specific
and inducible deletion of PTEN in epithelial cells as a model of
carcinogenesis has never been achieved. In the uterus, biallelic
deletion of PTEN has been achieved by crossing conditional PTEN-
KO mice with a mice expressing Cre under the progesterone
receptor promoter (PR-Cre) (Daikoku et al., 2008). PR-Cre mice
led to PTEN deletion in all progesterone-receptor-expressing cells,
which includes both epithelial and stromal cells. Similarly,
tamoxifen-induced activation of Cre in R26Cre-ERT mice results
in the deletion of PTEN both in epithelial and stromal
compartments (Lu et al., 2007).
Here, we describe a new tamoxifen-inducible mouse model for
inducible and conditional deletion of PTEN. Cre expression driven
by the chicken actin promoter (CAG) led to PTEN deletion mainly
in epithelial cells, but not in stromal, or hematopoietic, cells. Such
deletion caused development hyperplasias and neoplasias in some
tissues such as endometrium, prostate or thyroid, but not in other
epithelial tissues. We think that this model could be a valuable tool
to study the molecular mechanisms underlying PTEN-loss-induced
carcinogenesis and is suitable for the rapid assessment of anti-tumor
drug effectiveness.
RESULTS
Tamoxifen induces dose-dependent deletion of conditional PTEN
alleles in endometrial epithelial cells but not in stromal cells
Our group has experience in the study of the molecular mechanisms
that trigger endometrial carcinogenesis. To generate a mouse
model for endometrial carcinogenesis, we bred PTEN conditional-
KO (PTENfl/fl) mice (Lesche et al., 2002) with mice expressing Cre-
ERT (CAG-Cre-ERT) recombinase driven by the chicken β-actin
promoter (Hayashi and McMahon, 2002). After two generations,
we obtained mice carrying both PTEN floxed alleles and one copy
of the Cre-ERT transgene (CAG-Cre-ERT+/− PTENfl/fl). At 3 weeks
after birth, mice were weaned and, after 1 or 2 additional weeks,
they were intraperitoneally injected with 0.5, 1 or 2 mg of tamoxifen
(see Fig. 1A). After 7 days, mice were sacrificed and PTEN
expression in the uterus was analyzed by immunohistochemistry
(IHC) (Fig. 1B). Increasing doses of tamoxifen caused an increase
in the number of PTEN-negative cells in endometrial epithelium
(Fig.  1C). Interestingly, loss of PTEN resulted in mosaics of
epithelial cells retaining PTEN expression mixed with cells with a
complete loss of PTEN labeling. Surprisingly, stromal cells retained
PTEN immunostaining, which was comparable to that observed
in non-injected mice. To avoid non-desired or possible collateral
effects of tamoxifen, we chose the lowest dose (0.5 mg) for all future
experiments.
These results suggest that tamoxifen treatment causes PTEN
deletion preferentially in endometrial epithelial cells. To ascertain
whether the differences in PTEN ablation were caused by
differential Cre-ERT activity among cell types, we bred a CAG-Cre-
ERT mouse with a double-fluorescent Cre reporter mouse that
expresses membrane-targeted tandem dimer Tomato (mT) prior
to Cre-mediated excision and membrane-targeted green
fluorescent protein (mG) after excision (mT/mG mouse)
(Muzumdar et al., 2007). The resulting offspring was injected with
tamoxifen and 7 days later the expression of green or red
fluorescence in the uterus was monitored under confocal
microscope. Only epithelial cells of the endometrium switched from
red to green fluorescence, indicating that Cre-ERT was only active
in epithelial cells (Fig. 1D).
Tamoxifen-induced PTEN deletion led to rapid development of
endometrial hyperplasia and adenocarcinoma in situ
Next, we analyzed whether such PTEN deficiency would result in
the formation of endometrial proliferations. For this purpose, mice
were injected with tamoxifen and analyzed in three intervals of time
after tamoxifen injection: 0-2 weeks, 3-5 weeks and 6-8 weeks. For
each single animal sacrificed, uterus was dissected and analyzed
by routine hematoxylin and eosin (H&E) staining and PTEN IHC.
TRANSLATIONAL IMPACT
Clinical issue
PTEN, a lipid and protein phosphatase, is encoded by one of the most
frequently mutated tumor suppressor genes in human cancer. Loss of PTEN
function is associated with neoplastic transformation in multiple tissue types,
including breast, thyroid, prostrate and endometrial tissue. Heterozygous
PTEN+/– mice have been used successfully to investigate the role of PTEN in
carcinogenesis. However, the consequences of complete PTEN deletion remain
unclear, because studies using homozygotes have been limited owing to
embryonic lethality. The development of appropriate conditional models is
crucial to advance our understanding of the molecular mechanisms
underlying PTEN-associated carcinogenesis. Furthermore, such models would
enable us to investigate and assay new anti-neoplastic therapies.
Results
Here, the authors present a novel knockout mouse model that carries a
tamoxifen-inducible deletion of PTEN. They demonstrate that a single dose of
tamoxifen results in complete PTEN ablation, mainly in epithelial cells. Loss of
PTEN leads to extremely rapid, reproducible and efficient development of
endometrial hyperplasias and in situ carcinomas, prostate neoplasias and
thyroid hyperplasias. The team then administered the mTOR inhibitor
everolimus to the knockout mice. A dramatic decrease in the progression of
endometrial and thyroid carcinomas was observed in the presence of
everolimus, validating the model as a tool to investigate drug efficacy. 
Implications and future directions
The specificity of PTEN deletion in epithelial cells, together with the high
incidence and speed of tumor formation, makes this model an attractive tool
to investigate new targeted therapies to treat cancers that are induced by
PTEN deficiency. In addition to its use as a platform to test anti-tumor drugs,
this model might be useful for the study of molecular mechanisms involved in
neoplastic growth caused by PTEN loss, particularly in endometrial, prostate
and thyroid tissue. Furthermore, these investigations will be possible within a















    




A new inducible PTEN-KO mouseRESEARCH ARTICLE
In animals analyzed in the first period of time (0-2 weeks), PTEN
was deleted in endometrial epithelial cells, but we did not observe
any increase in the number of epithelial glands or gross
morphological alteration (Fig. 2A,D). However, morphological
alteration became evident between 3 and 5 weeks after tamoxifen
administration. Around 40% of mice displayed complex
endometrial hyperplasia and an additional 50% of them already
developed complex atypical hyperplasia and endometrial in situ
adenocarcinoma (Fig.  2B,D), showing architectural complexity,
cribriform pattern and solid arrangement. All neoplastic growths
were restricted to the endometrium. Between 6 and 8 weeks, 100%
of mice showed endometrial in situ adenocarcinoma (Fig. 2C,D).
Strikingly, PTEN immunostaining revealed that tumoral tissue was
strictly composed of PTEN-negative glands, whereas glands
retaining PTEN expression were completely normal. Moreover,
stromal cells from all tamoxifen-injected mice displayed a positive
PTEN immunostaining that was indistinguishable from that
observed in non-injected mice. We want to mention that we did
not extend the study for longer times because, by 8 weeks after
tamoxifen injection, most mice showed breathing difficulties,
lethargy, ruffled fur and hunched posture. To avoid unnecessary
animal suffering, mice were euthanized. Such aggravation of health
was attributed to the appearance of endometrial and other
neoplastic processes (see following parts of Results for explanation).
For that reason, mice were not allowed to survive for long enough
for the tumors to invade the myometrium and to metastasize to
other organs.
Because chronic tamoxifen exposure is a risk factor for the
development of endometrial lesions, we injected control mice
carrying both PTEN floxed alleles but lacking Cre-ERT expression.
At 8 weeks after tamoxifen injection, Cre-ERT−/− PTENfl/fl mice did
not show any morphological alteration nor changes in PTEN
immunoreactivity (supplementary material Fig. S1).
Tamoxifen-induced Cre-ERT recombination occurs mainly in
epithelial tissues
The results obtained with endometrial tissue enabled us to
investigate whether Cre-ERT expression would also be restricted
to epithelial cells of other tissues or organs. To this end, we analyzed
different tissues from CAG-Cre-ERT mT/mG mice, such as lung,
colon, thyroid, liver and kidney. mT/mG mice lacking Cre-ERT
expression showed only red fluorescence, indicating no
recombination. In contrast, CAG-Cre-ERT mT/mG mice injected
with tamoxifen displayed a switch from red to green fluorescence
(Fig. 3A). Interestingly, most of the tissues that were analyzed
displayed green fluorescence in epithelial cells but not in stromal
or other cell types. In the lung, green fluorescence appeared in
bronchiolar epithelial cells. In colon, a red-to-green switch was
observed also in epithelial cells. In the kidneys, green cells appeared
in epithelial cells of renal tubules and nephrons. In the thyroid,
Fig. 1. Differential Cre-ERT activity and PTEN deletion in endometrial epithelial and stromal compartments. (A)Schematic showing the experimental set-
up for tamoxifen (TAM) treatment. Briefly, mice were weaned 3 weeks after birth and genotyped. At 4-5 weeks old, animals were given a single intraperitoneal
dose of tamoxifen, or corn oil as a vehicle (con). Mice were sacrificed 7 days later. (B)Tamoxifen induces a dose-dependent deletion of PTEN. PTEN
immunohistochemistry corresponding to CAG-Cre-ERT+/− PTENfl/fl 7 days after tamoxifen injection. Note that stromal cells remained positive for PTEN staining.
(C)Quantification of the percentage of endometrial epithelial cells displaying negative for PTEN immunostaining after injection of the indicated doses of
tamoxifen. (D)Analysis of tamoxifen-induced recombination in CAG-Cre-ERT mT/mG reporter mice. Representative images corresponding to CAG-Cre-ERT+/−
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green fluorescence was observed in follicular cells. These results
indicate that Cre-ERT is mainly expressed in epithelial cells.
We also analyzed bone marrow and spleen from mT/mG mice
injected with tamoxifen. None of the lymphoid organs displayed a
switch from red to green fluorescence, suggesting the absence of
Cre activity in those organs (Fig. 3B).
Tamoxifen-induced PTEN deletion results in a rapid development
of prostate intraepithelial neoplasias and thyroid hyperplasia
Tamoxifen-induced Cre-ERT activity was not restricted to
endometrial epithelial cells, but was also observed in other epithelial
tissues. Because loss of PTEN has been observed in different
carcinomas, we extended our investigations to tissues in which
PTEN deletion has been associated with carcinogenesis. Among
them, PTEN is frequently mutated in thyroid and prostate
malignancies. Moreover, conditional deletion of PTEN in the
thyroid or the prostate leads to the formation of neoplastic
processes.
At 8 weeks after tamoxifen injection, we dissected prostates and
thyroids from CAG-Cre-ERT+/− PTENfl/fl mice and analyzed their
histopathological features and PTEN expression. As was found for
the endometrium, induction of Cre-ERT activity caused a complete
loss of PTEN immunoreactivity in epithelial prostatic cells but not
in stromal cells. More importantly, PTEN loss resulted in the
development of prostate intraepithelial neoplasias (PIN) (Fig. 4A).
Mice injected with vehicle (corn oil) or tamoxifen-injected mice
carrying conditional PTEN alleles but lacking Cre expression
(CAG-Cre-ERT−/− PTENfl/fl) displayed normal morphology and no
decrease of PTEN expression. Histopathological analysis and
cytokeratin immunostaining revealed high-grade neoplastic growth
(PIN) (Fig. 4B). All mice that were studied developed high-grade
PIN 8 weeks after tamoxifen injection (Fig. 4C). Neoplastic growth
correlated with an increase in Ki-67 immunostaining, suggesting
increased proliferation of prostatic tumoral cells.
Thyroids from CAG-Cre-ERT+/− PTENfl/fl mice injected with
tamoxifen were substantially bigger than those dissected from non-
injected mice (Fig. 5A). Pathological  analysis of tamoxifen-injected
mice revealed the presence of follicular nodular hyperplasia but
not invasive thyroid carcinomas (Fig. 5B). Surprisingly, control mice
also displayed some focal nodular thyroid hyperplasia. Therefore,
Fig. 2. Tamoxifen-induced PTEN deletion causes rapid and reproducible development of endometrial hyperplasia and in situ adenocarcinoma of the
endometrium. (A-D)Comparison of histopathology and PTEN expression of Cre-ERT+/− PTENfl/fl mice injected with tamoxifen (TAM) or corn oil (CON) at different
time points. (A-C)Representative images showing PTEN immunohistochemistry (bottom panels) and H&E staining (top panels) of uterus from mice sacrificed in
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Fig. 3. Evaluation of inducible and tissue-specific Cre-ERT recombinase
activity in the double-fluorescent mT/mG reporter mice. CAG-Cre-ER−/−
mT/mG+/− and CAG-Cre-ERT+/− mT/mG+/− mice were given a single dose of
tamoxifen as described in Fig. 1. After 7 days, different tissues were fixed and
analyzed for the presence of green (indicative of Cre-ER recombination) or red
(indicative of lack of Cre-ER recombination) fluorescence. (A)Representative
confocal images corresponding to organs containing epithelial tissues
(thyroid, liver, colon, kidney and lung) showing green fluorescence after
tamoxifen injection. (B)Representative images of hematopoietic and
lymphoid organs (bone marrow and spleen). Note absence of green
fluorescence.
Fig. 4. Tamoxifen-induced PTEN deletion causes the rapid development
of prostate intraepithelial neoplasia (PIN). Prostates from CAG-Cre-ERT−/−
PTENfl/fl or CAG-Cre-ERT+/− PTENfl/fl were analyzed 6-8 weeks after tamoxifen
(TAM) or corn oil (CON) injection. (A)Representative images of CAG-Cre-ERT+/−
PTENfl/fl tamoxifen-treated males showing high-grade PIN lesions and PTEN-
negative immunostaining. Control mice displayed normal histology and
retained PTEN immunostaining. (B)Representative images of cytokeratin
staining, showing increased immunostaining in high-grade PIN epithelial cells.
(C)Quantification of the percentage of mice displaying prostatic lesions 6-8
weeks after tamoxifen injection. (D)Representative images (top) and
quantification (bottom) of Ki-67 immunostaining in prostates of CAG-Cre-
ERT–/– PTENfl/fl mice injected with tamoxifen, and CAG-Cre-ERT+/− PTENfl/fl mice
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we hypothesized that, in the thyroid, Cre-ERT activity was induced
in the absence of tamoxifen, resulting in the deletion of PTEN in
some cells. To test this hypothesis, we analyzed PTEN expression
by immunofluorescence in mice injected or not with tamoxifen.
PTEN expression was completely lost in thyroid follicles in CAG-
Cre-ERT+/− PTENfl/fl mice injected with tamoxifen (Fig.  5C). In
control CAG-Cre-ERT+/− PTENfl/fl mice, injected with corn oil,
PTEN expression was retained in zones of normal tissue and was
undetectable in hyperplastic areas. This result suggests that
spontaneous (tamoxifen-independent) Cre-ERT activity in the
thyroid leads to PTEN ablation even in the absence of tamoxifen.
Despite such leaking of Cre activity, injection of tamoxifen resulted
in a more severe thyroid hyperplasia and increased thyroid size. It
is worth noting that, by 8 weeks after tamoxifen treatment, such
an increase in thyroid size caused severe breathing difficulties,
causing a dramatic worsening of animal health. For this reason,
animals required euthanization.
PTEN is efficiently deleted in other epithelial organs but does not
trigger neoplastic growth
As we describe above, 100% of tamoxifen-treated CAG-Cre-ERT+/−
PTENfl/fl mice displayed endometrial hyperplasia/adenocarcinoma
in situ or PIN. However, mT/mG reporter mice revealed Cre-ERT
activity in other epithelial tissues. For this reason, we decided to
analyze the formation of neoplastic growth in other tissues from
tamoxifen-injected mice, such as the lungs, kidneys, liver or colon.
IHC revealed loss of PTEN immunoreactivity in epithelial cells of
the four organs. In the kidney, loss of PTEN immunostaining was
observed in epithelial tubular cells (Fig. 6A). In the liver, hepatocytes
showed loss of PTEN expression (Fig. 6B). In the lung, loss of PTEN
was restricted to bronchiolar columnar epithelial cells (Fig.  6C).
Similarly, in colonic tissue, PTEN labeling was also lost in epithelial
cells (Fig.  6D). Despite the loss of PTEN observed in all those
tissues, none of them displayed morphological alterations or
neoplastic growth. It is noteworthy that specific deletion of PTEN
in all four tissues correlated with Cre-ERT recombinase activity,
evidenced by experiments carried out with mT/mG reporter mice
(Fig. 2A).
Finally, we analyzed the expression of PTEN in lymphoid tissues.
In PTEN+/− mice, tissue conditional PTEN deletion in lymphoid
tissues or the inducible ablation of PTEN under the control of
R26Cre-ERT led to the development of hematological malignancies
such as leukemia and lymphoma. Such malignancies were often
the cause of death, thereby limiting the study of PTEN deficiency
in other organs in which PTEN alterations are important.
Immunohistochemical analysis showed that PTEN expression was
similar in mice injected with tamoxifen and control animals in both
bone marrow (Fig.  6E) and spleen (Fig.  6F). Concordantly,
pathological analysis of lymphoid organs demonstrated the absence
of malignancies. Again, the absence of PTEN deletion correlated
with the lack of Cre activity in bone marrow and spleen (see Fig. 2B).
These results suggest that PTEN is not excised in lymphoid organs
because of the lack of Cre-ERT activity in those tissues.
Everolimus reduces the development of endometrial in situ
carcinoma and thyroid hyperplasia
Here, we describe a new mouse model that rapidly develops
endometrial hyperplasia, intraepithelial carcinoma, PIN and thyroid
nodular hyperplasia with 100% incidence. Such features make this
mouse an attractive model to test the efficacy of anti-neoplastic drugs
targeting the PI3K-Akt pathway. Inhibition of mTOR has been
reported as an effective therapy for tumors that have alteration in
PI3K-Akt signaling (Engelman, 2009; Hollander et al., 2011). To
demonstrate that our model is a suitable tool to test the efficacy of
anti-neoplastic drugs, we treated tamoxifen-injected mice with the
mTOR inhibitor everolimus (also known as RAD001). For this
purpose, 1-2 weeks after weaning, mice were injected with tamoxifen
to induce PTEN excision. At 5 weeks after tamoxifen injection, female
mice were injected daily with 10 μg everolimus/g body weight for
Fig. 5. PTEN inactivation leads to the development of thyroid hyperplasia.
(A)Comparison of representative thyroids from CAG-Cre-ERT+/− PTENfl/fl mice 6-
8 weeks after being injected with corn oil (CON) or tamoxifen (TAM).
(B)Representative images of hyperplasia in thyroids dissected from three
corn-oil-injected (CON) and three tamoxifen-injected (TAM) mice.
(C)Immunofluorescence staining showing PTEN loss in CAG-Cre-ERT+/− PTENfl/fl
thyroids. Representative images showing PTEN immunofluorescence of mice
injected with corn oil displaying no hyperplasic nodules (CON), mice injected
with corn oil displaying hyperplasic nodules (CON-Nodule) or mice injected
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15 consecutive days and sacrificed (see Fig. 7A). As we mentioned
above, tamoxifen-injected mice showed lethargy, ruffled fur, hunched
posture and required euthanization. In contrast, everolimus-injected
mice remained healthy and active (Fig. 7B). Pathological analysis of
the endometrium revealed that everolimus caused a marked
reduction in the severity of endometrial lesions (Fig. 7C), decreasing
the percentage of mice suffering from endometrial in situ
adenocarcinoma from 100% to 25%. The rest of the endometrium
from everolimus-treated mice was normal (25%) or hyperplasic
(50%). Such a reduction in endometrial lesions correlated with a
reduction of Ki-67, suggesting that everolimus caused a reduction
of cell proliferation (Fig. 7C). Similarly, everolimus treatment caused
a dramatic reduction in thyroid size and decreased the number of
Ki-67-positive cells (Fig. 7D).
DISCUSSION
The development of appropriate mouse models of human tumors
has been crucial to progress the understanding of cancer biology
and to identify better therapeutic and diagnostic strategies. Here,
we describe a new mouse model that allows tamoxifen-inducible
deletion of PTEN, which results in a rapid development of
endometrial hyperplasia and intraepithelial carcinoma, PIN and
thyroid nodular hyperplasia.
Molecular alterations of PTEN are very frequent in endometrial
carcinomas. To date, only two existing models to achieve
conditional deletion of PTEN in the endometrium have been
reported: conditional deletion of PTEN has been achieved by
breeding conditional PTEN KO mice with mice expressing PR-Cre
(Daikoku et al., 2008) or inducible R26Cre-ERT (Lu et al., 2007).
Both strategies resulted in ablation of PTEN in both epithelial and
stromal cells (apart from other non-endometrial tissues). In
contrast, our mouse constitutes the first that allows inducible and
epithelial-cell-specific PTEN deletion in endometrial epithelial
cells. It is widely accepted that endometrial carcinomas, as other
types of carcinomas, arise as a result of the accumulation of
mutations in epithelial cells. By contrast, it is well-known that
stromal cells can affect tumor behavior (Bhowmick et al., 2004).
Such an important role has been recently supported by results
showing that specific inactivation of PTEN in mammary stromal
cells leads to accelerated breast tumorigenesis (Trimboli et al., 2009;
Wallace et al., 2011). Therefore, it is likely that deletion of PTEN
in endometrial stromal cells can affect the progression of tumoral
epithelial cells. To this end, we think that specific deletion of PTEN
in the epithelium is important to understand the cell-autonomous
mechanisms that are involved in carcinogenesis. So far, specific
PTEN deletion in endometrial epithelial cells has only been
achieved by tissue recombination experiments, in which PTEN-
deficient epithelial cells have been recombined with wild-type
stromal cells and implanted under the renal capsule of
immunocompromised mice (Memarzadeh et al., 2010). Because
PTEN excision is restricted to the epithelial compartment of the
endometrium, our model provides a valuable tool to study cell-
autonomous mechanisms of carcinogenesis. Another important
point is that PTEN is not deleted in epithelial cells in any organ,
but only in those of some specific locations. One single endometrial
gland is a mosaic of cells lacking PTEN side-by-side with cells
retaining PTEN expression, which mimics what happens in normal
human endometrium. PTEN-retaining cells show a completely
normal phenotype, strongly demonstrating that carcinogenesis
arises exclusively from PTEN-deficient cells. Moreover, in our
model, induction of PTEN excision is performed adult mice. This
is an important point because, in most tissue-specific conditional
models, the onset of deletion depends on the activity of the tissue-
specific promoter, but it cannot be temporally regulated. Because
hyperplastic and neoplastic processes of human endometrial,
prostatic or thyroidal tissues are diseases that are predominantly
found in adults, induction of PTEN excision in adult mice mimics
the onset of those human malignancies.
We have observed that one single injection of tamoxifen results
in the ablation of PTEN in many epithelial cell types. However, we
only found endometrial hyperplasia, intraepithelial carcinoma, PIN
and thyroid nodular hyperplasia, but did not observe the formation
of neoplasia in other epithelial tissues such as the kidney, lung or
colon. Previous works have demonstrated that conditional
inactivation of PTEN in the lung or colon leads to the development
of neoplasias. Such differences can be explained by genetic
Fig. 6. PTEN loss does not cause rapid neoplastic growth in other epithelia
or in hematopoietic or lymphoid tissues. Representative images of H&E
staining and PTEN immunohistochemistry corresponding to (A) kidney, (B)
liver, (C) lung, (D) colon, (E) bone marrow and (F) spleen from CAG-Cre-ERT+/−
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Fig. 7. mTOR inhibition reduces endometrial lesions and thyroid hyperplasia. (A)Schematic representation of the protocol used for everolimus
administration. Briefly, 5 weeks after tamoxifen injection, animals started to receive a single daily intraperitoneal dose of everolimus for 14 consecutive days and
then they were sacrificed. (B)At 7 weeks after tamoxifen injection (TAM), mice exhibited lethargy, ruffled fur and hunched posture. Animals treated with
everolimus (TAM+EVE) remained healthy and active, similar to controls (CON). (C)H&E staining and PTEN immunohistochemistry images corresponding to
endometria from mice treated with corn oil (CON), tamoxifen (TAM) or tamoxifen plus everolimus (TAM+EVE). Everolimus-treated females showed reduced
lesions and PTEN-negative healthy areas. Percentage of animals developing endometrial hyperplasia (EH) and endometrial in situ adenocarcinomas (EC) after
injection of corn oil (CON), tamoxifen (TAM) or tamoxifen and everolimus (TAM+EVE) are shown in the top graph. Representative images (bottom left) and
quantification (bottom right) of Ki-67 immunostaining performed on uterus dissected from mice injected with corn oil (CON), tamoxifen (TAM) or tamoxifen plus
everolimus (TAM+EVE). (D)Representative images of thyroids dissected from mice injected with corn oil (CON), tamoxifen (TAM) or tamoxifen plus everolimus
(TAM+EVE). Everolimus treatment also reduced thyromegaly in tamoxifen-injected mice. Everolimus caused a marked decrease of the index of proliferation, with
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background. It has been demonstrated that genetic background
affects the development of PTEN-loss-induced tumors in mice
(Freeman et al., 2006). Spatiotemporal expression of Cre can be
different depending on genetic background (Hébert and
McConnell, 2000; Smith, 2011; Wang, 2009), leading to different
patterns of recombination of both the Cre and the floxed mice. To
achieve inducible inactivation of PTEN, we used a transgenic mouse
line in which Cre-ERT is expressed under the chicken β-actin
promoter. Theoretically, Cre should be ubiquitously expressed in
most tissues of the mouse at embryonic and adult stages (Hayashi
and McMahon, 2002). However, using a fluorescent reporter
mouse, we detected Cre activity mainly in epithelial cells
throughout the whole mouse body, but there was little or no activity
in hematopoietic or mesenchymal cells. It is worth mentioning that
Cre expression completely correlated with PTEN deletion. To this
regard, the lack of expression in hematopoietic cells is an important
issue. Ablation of PTEN in hematopoietic cells leads to a rapid
development of lymphoproliferative and myeloproliferative
disorders, shortening mouse lifespan and conditioning the
development and study of other PTEN-induced malignancies. Our
model overtakes this limitation.
Conditional models allow deletion of a gene in one single tissue
and the development of one single type of neoplasm. Our mouse
model could represent a platform to assay the effects of
chemotherapeutic drugs on hyperplasia and carcinoma in three
different organs using one single mouse strain. The use of one single
mouse strain reduces the number of mice used and the economic
costs of investigations. As a proof for such application, we have
used our PTEN mouse model to evaluate the effects of mTOR
inhibition by everolimus on endometrial hyperplasia, carcinoma
and thyroid hyperplasia. The involvement of mTOR and Akt as
downstream signaling effectors of PTEN deficiency has been
strongly supported by crossing PTEN hemizygous mice with mice
carrying genetic mutations in PTEN downstream effectors.
Deficiency in either PDK1 (Bayascas et al., 2005) or Akt-1 (Chen
et al., 2006) signaling reduces endometrial carcinogenesis in
PTEN+/− mice. Inhibition of mTOR has been reported to reduce
the growth of thyroid (Yeager et al., 2008), endometrial (Milam et
al., 2007; Podsypanina et al., 2001) or prostate (Zhang et al., 2009)
carcinomas in PTEN-deficient mouse models. In our model,
everolimus is able to reduce neoplastic growth, validating this model




Mice were housed in a barrier facility and pathogen-free procedures
were used in all mouse rooms. Animals were kept in a 12-hour
light-dark cycle at 22°C with ad libitum access to food and water.
All procedures performed in this study followed the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals and were compliant with the guidelines of Universitat de
Lleida. Floxed homozygous PTEN (C;129S4-Ptentm1Hwu/J;
referred to here as PTENfl/fl), Cre-ERT [B6.Cg-Tg(CAG-Cre/Esr1*
5Amc/J] and reporter mT/mG [B6.129(Cg)-
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J] mice were
obtained from the Jackson Laboratory (Bar Harbor, ME). Cre-
ERT+/− PTENfl/fl mice were bred in a mixed background (C57BL6;
129S4) by crossing PTENfl/fl and Cre-ERT+/− mice. To obtain mice
carrying both PTEN floxed alleles (PTENfl/fl) and a single Cre-ERT
(Cre-ERT+/−), Cre-ERT+/− PTENfl/+ mice were backcrossed with
PTENfl/fl mice. At 3 weeks after birth, animals were weaned and
genotyped as previously described (Lesche et al., 2002; Hayashi and
McMahon, 2002).
Tamoxifen administration
Tamoxifen (Sigma-Aldrich T5648, St Louis, MO) was dissolved in
100% ethanol at 100 mg/ml. Tamoxifen solution was emulsified in
corn oil (Sigma-Aldrich C8267) at 10 mg/ml by vortexing. To induce
PTEN deletion, adult mice (4-5 weeks old) were given a single
intraperitoneal injection of 0.5 mg of tamoxifen emulsion (30-35
μg per mg body weight).
Cre-ERT reporter assays
For reporter assays of Cre activity, Cre-ERT+/− and mT/mG+/− mice
were bred. The resulting Cre-ERT−/− mT/mG+/− and Cre-ERT+/−
mT/mG+/− animals were weaned and injected with tamoxifen. At
1 week after tamoxifen treatment, animals were sacrificed and
organs were collected and fixed in 4% PFA for 4  hours at room
temperature. Samples were cryoprotected in PBS with 30% sucrose
overnight at 4°C and embedded in OCT (VWR International). 8-
μm sections of frozen tissue were cut with cryostat and nuclei were
counterstained with Hoescht and samples mounted with
PBS:glycerol (1:1). Tissue immunofluorescence was visualized using
a confocal microscope (Olympus, Tokyo, Japan). Confocal images
were edited using FluoView software (Olympus).
Histopathology and immunohistochemical analysis
After tamoxifen injection, animals were euthanized by cervical
dislocation and organs were collected and formalin-fixed overnight
at 4°C. One part of the organs was embedded in paraffin for
histological examination. Another part was cryoprotected in PBS
with 30% sucrose and embedded in OCT (VWR International) for
immunofluorescence staining. H&E-stained samples were reviewed
and evaluated by two pathologists, following uniform pre-
established criteria. Paraffin blocks were sectioned at 3 μm, dried
for 1 hour at 65°C before the pre-treatment procedure of
deparaffinization, rehydration and epitope retrieval in the Pre-
Treatment Module, PT-LINK (DAKO), at 95°C for 20 minutes in
50× Tris/EDTA buffer, pH 9. The antibodies used were anti-PTEN
(Dako, Denmark, clone 6H2.1, 1/100 dilution), Ki-67 (Dako,
Denmark, clone TEC-3, 1/50 dilution) and high-molecular-weight
cytokeratin (HMW-CK, Dako, Denmark, clone 34βE12, ready to
use). The reaction was visualized with the EnVision FLEX detection
kit (Dako, Denmark) for PTEN and HMW-CK and polyclonal
rabbit anti-rat immunoglobulins/biotinylated and streptavidin
(Dako, Denmark) for Ki-67 using diaminobenzidine chromogen as
a substrate. Images were taken with a Leica DMD108 microscope.
To optimize PTEN immunostaining with 6H2.1 antibody, we first
performed IHC on both wild-type and PTEN-deficient mouse
endometrium with 1/100, 1/200 and 1/300 dilutions of the antibody.
The staining pattern was similar with 1/100, 1/200 and 1/300
dilutions, but the signal was weaker at higher dilutions. We chose
1/100 dilution as the best signal-to-background ratio for further
experiments (supplementary material Fig. S2A). To demonstrate
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samples containing PTEN-expressing and PTEN-null glands was
stained with anti-PTEN antibody (supplementary material
Fig. S2B). To further prove the specificity of PTEN immunostaining,
PTEN-proficient and PTEN-deficient endometrial carcinoma cell
lines were immunostained with PTEN 6H2.1 antibody. For this
purpose, the PTEN-deficient RL95 cell line was transfected with a
plasmid encoding wild-type PTEN and the PTEN-proficient cell
line HEC-1A was transfected with a plasmid encoding PTEN
shRNA to downregulate endogenous levels of PTEN expression.
Paraffin blocks of RL95 and HEC-1-A were constructed and
processed for PTEN immunostaining as described above. The
results of PTEN immunostaining on transfected RL95 and HEC-
1A cells are shown in supplementary material Fig. S2C.
Immunofluorescence
Frozen tissue was cut in 8-μm slices using a cryostat. Slides were
washed in PBS with Tween 0.05% (PBST) for 30 minutes followed
by PBS wash (once for 5  minutes) and incubated in blocking
solution (PBST with 5% normal goat serum) for 1 hour at room
temperature. Sections were incubated overnight at 4°C with rabbit
polyclonal anti-PTEN antibody (catalog no. 9552; Cell Signaling,
dilution 1/50). Slides were washed four times in PBST for 5 minutes
and incubated for 1 hour at room temperature with Alexa-Fluor-
488-labeled secondary antibodies. Cell nuclei were counterstained
with 5 μg/ml Hoechst 33342 dye. Immunofluorescence was
visualized using a confocal microscope (Olympus, Tokyo, Japan).
Everolimus treatment
At 5 weeks after tamoxifen injection, we administered 10 mg/kg
body weight/day of Everolimus RAD001 (Sigma-Aldrich) as a
microemulsion (2% w/v) diluted in distilled water by intraperitoneal
injection. Animals were sacrificed and organs were collected after
14 days of treatment.
Proliferation analysis
Five representative fields of each tissue were photographed for each
animal. Proliferation was calculated as the percentage of Ki-67-
positive nuclei to the total number of nuclei of each field (1000-2000
total nuclei were evaluated for each animal). Counting was performed
using ImageJ software (Wayne Rasband, NIH, Bethesda, MD).
Statistical analysis
Experiments were performed at least three times and statistical
significance was determined by Student’s t-test with P≤0.05 (*) or
P≤0.001 (**).
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